The company has assembled a team of experts and received significant financial and technical support from the Foundation Fighting Blindness, which has invested nearly $700 million in research for blinding retinal diseases over the last 46 years. Nacuity's drug candidates focus on the treatment of ocular oxidative stress and other ocular diseases, with the goal of helping healthcare professionals treat patients suffering from these disorders. Through a milestone-based matching program grant from FFB, Nacuity plans to conduct Phase 1 and Phase 2 trials for its NPI-001 development program.